News : fungal

View:
 

Found press releases

 

MOBERG DERMA SECURED SEK 35 MILLION IN NEW SHARE ISSUE

8/24/2009 2:00 AM EST  -   MOBERG DERMA AB
The pharmaceutical company Moberg Derma recently secured SEK 35 million in a new share issue. Both existing and new shareholders subscribed for shares in the issue. More than SEK 100 million has now been raised for its operations since the company was established in March 2006.
“We are very pleased with the interest shown by investors what has been a difficult market climate in recently. The new share issue has...
Peter Wolpert, CEO Moberg Derma
 

MOBERG DERMA REPORTS POSITIVE PHASE III RESULTS FOR K101 AGAINST NAIL FUNGUS

11/20/2008 8:50 AM EST  -   MOBERG DERMA AB
Moberg Derma AB reports today positive results from a phase III clinical study for K101 against nail fungus (onychomycosis). In the study, almost 500 patients were treated during six months with K101 or a placebo. The results showed that significantly more patients receiving K101 were cured of their fungal infection (p=0.001). The patients' subjective evaluation of the treatment effect revealed distinct benefits...